Drug Profile
Measles DNA vaccine - Johns Hopkins/Vical
Alternative Names: Bivalent DNA vaccine encoding measles haemagglutinin and fusion glycoproteins - Vical; Measles plasmid DNA vaccine - Vical; Vaxfectin-formulated DNA vaccine for measles - Johns Hopkins/VicalLatest Information Update: 06 Sep 2019
Price :
$50
*
At a glance
- Originator Johns Hopkins University; Vical
- Class DNA vaccines; Measles vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Measles
Most Recent Events
- 31 Aug 2019 Brickell Biotech has merged with Vical to form Brickel Biotech Inc
- 16 Jul 2016 No recent reports of development identified for preclinical development in Measles in USA (IM, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Measles in USA (Intradermal, Injection)